Cheryl Barton

The European Union aims to become the most attractive place for life science by 2030.

Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated steatohepatitis arena.

The deadline for stakeholder consultation submissions on the new and updated regulations is Oct. 7, 2025.

EMA is phasing out animal testing and is asking pharmaceutical companies to use new approach methodologies.

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.

EMA has published recommendations to address potential radiopharmaceutical shortages.

The European Union is discussing ways to reduce Europe’s over-reliance on imports of APIs.

New TCR-T cell therapies look promising in the treatment of haematological and solid tumours.

The Act is the European Union’s plan to avert drug shortages.

The Biotech and Biomanufacturing Hub will help European companies access funding, navigate regulations, and speed up market access.

European biopharma companies are looking beyond GLP-1s.

EMA introduced its New Fee Regulation in January 2025, but what impact will the new fees and charges have on medicine developers?

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.

The European Commission has developed a roadmap aimed at reversing the rising trend of cancer across the European Union.

Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.

Regulators, EMA and HMA, have published principles and recommendations on the use of LLMs, which are being increasingly used for daily tasks.

What impact will the AI Act have on pharma and digital medicine?

Germany’s Medical Research Act allows pharmaceutical companies to keep drug prices confidential.

Innovative solutions are making personalized cell and gene therapies accessible to all.

EMA is promoting the use of RWD in decision-making and has started a public consultation to review its draft recommendations.

Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.

The European pharma industry needs to be prepared for the new clinical data requirements.

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

The UK’s IRP increases flexibility and will help speed up product approvals and patient access to medicines.

Novel molecular glues are transforming targeted protein degradation.

The EHDS aims to increase access to health data, but how will it impact pharma?

What does the 2024 VPAS mean for pharma?

New radiotherapeutic agents are making headway in hard-to-treat cancers.

The new framework will position the UK as an attractive prospect for new medicine manufacturers.

Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.